Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030224 · ClinicalTrials.gov registry record · Phase 1
This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01030224 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT01030224, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety, tolerability and PK of AZD9742 after single IV doses.
Interventions
- DRUG AZD9742
- DRUG Placebo to match AZD9742
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030224
The ClinicalTrials.gov registry entry for NCT01030224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD9742 is the first listed.
NCT01030224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030224 about?
NCT01030224 is a clinical study titled "This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects". The main purpose of this study is to assess the safety, tolerability and PK of AZD9742 after single IV doses.
What is the current status of trial NCT01030224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2009-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01030224?
The interventions under investigation include: AZD9742 (DRUG), Placebo to match AZD9742 (DRUG).
Who is sponsoring clinical trial NCT01030224?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.